Zheng Yuling, Xu Yafei, Huang Bixin, Mai Ying, Zhang Yiwen, Zhang Zhongqi
Department of Anesthesiology, the Affiliated Shunde Hospital of Jinan University, Foshan, China.
Department of Anesthesiology, Shunde Hospital of Southern Medical University, Foshan, China.
Front Pharmacol. 2022 Sep 20;13:956392. doi: 10.3389/fphar.2022.956392. eCollection 2022.
This study aimed to determine the optimal dose of propofol combined with esketamine to inhibit the response to gastroscope insertion in elderly patients. This is a prospective, non-controlled, non-randomized, single-center study. Elderly patients aged 65-80 years were enrolled in the study with the American society of anesthesiologists (ASA) physical status I or II undergoing elective gastroscopy. All patients were administered propofol after an intravenous esketamine at the dosage of 0.3 mg/kg 30 s, the subsequent dose of propofol was determined by the response of the previous patient to gastroscope insertion (choking, body movement, etc.) using Dixon's up-and-down method. The initial dose of propofol administered to the first elderly patient was 3.0 mg/kg, and the standard ratio of propofol dose in adjacent patients was 0.9. At least six crossover points were obtained before the conclusion of the study. By using Probit analysis the median effective dose (ED), 95% effective dose (ED), and the corresponding 95% confidence interval (CI) for propofol were determined. The study continued until we obtained seven crossover points and 32 elderly patients (17 males and 15 females) were collected. The ED of propofol combined with esketamine inhibiting response to gastroscope insertion in elderly patients were found to be 1.479 mg/kg (95% CI 1.331-1.592 mg/kg), and ED was found to be 1.738 mg/kg (95% CI 1.614-2.487 mg/kg). According to the present study, propofol combined with 0.3 mg/kg esketamine is safe and effective for elderly patients undergoing gastroscopy. The ED and ED doses of propofol inhibiting response to gastroscope insertion in elderly patients when combined with 0.3 mg/kg esketamine were 1.479 and 1.738 mg/kg, respectively, without apparent adverse effects.
本研究旨在确定丙泊酚联合艾司氯胺酮抑制老年患者胃镜插入反应的最佳剂量。这是一项前瞻性、非对照、非随机、单中心研究。纳入年龄在65 - 80岁、美国麻醉医师协会(ASA)身体状况为I或II级、接受择期胃镜检查的老年患者。所有患者在静脉注射0.3 mg/kg艾司氯胺酮30秒后给予丙泊酚,随后丙泊酚的剂量根据前一位患者对胃镜插入的反应(呛咳、身体移动等)采用Dixon上下法确定。给予首位老年患者的丙泊酚初始剂量为3.0 mg/kg,相邻患者丙泊酚剂量的标准比值为0.9。在研究结束前至少获得六个交叉点。通过概率分析确定丙泊酚的半数有效剂量(ED)、95%有效剂量(ED)及相应的95%置信区间(CI)。研究持续进行直至获得七个交叉点,共收集32例老年患者(17例男性和15例女性)。发现丙泊酚联合艾司氯胺酮抑制老年患者胃镜插入反应的ED为1.479 mg/kg(95% CI 1.331 - 1.592 mg/kg),ED为1.738 mg/kg(95% CI 1.614 - 2.487 mg/kg)。根据本研究,丙泊酚联合0.3 mg/kg艾司氯胺酮对接受胃镜检查的老年患者安全有效。丙泊酚联合0.3 mg/kg艾司氯胺酮抑制老年患者胃镜插入反应的ED和ED剂量分别为1.479和1.738 mg/kg,且无明显不良反应。